HalioDx
Providing oncologists and biopharma with first-in-class immune-based diagnostic products and services.
- biotechnology
- horizon europe
- dt and ls
- woman founder
- spinout
- biotech and pharma
- radar de l'innovation
- risk management
- analytics
- testing
- tech for business
- oncology
- eit ecosystem
- observatoire industrial tech
- predictive analytics
- observatoire deeptech
- medical testing
- eit health
- biotech, medtech and e-health
- eit supernovas
- go global (eit health)
- go global 2019 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€260m Valuation: €260m | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 23417 % |
| EBITDA | 0000 | 0000 |
| % EBITDA margin | (410 %) | (18 %) |
| Profit | 0000 | 0000 |
| % profit margin | (433 %) | (3 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
HalioDx is a pioneering diagnostics company specializing in the field of immuno-oncology. The company focuses on developing and commercializing diagnostic tests that assess the immune contexture of tumors, which is the immune environment surrounding a tumor. This helps in predicting the risk of relapse in early-stage cancer patients, particularly in colorectal cancer. HalioDx serves clinical centers, oncologists, and healthcare providers, offering them advanced tools to personalize cancer treatment and improve patient outcomes. The company operates in the global healthcare market, with a significant presence in regions like Latin America through partnerships with major diagnostics providers like DASA. HalioDx's business model revolves around the sale of diagnostic tests and related services, generating revenue through direct sales and strategic partnerships. The company leverages its proprietary technology, Immunoscore, which combines PD-L1 with CD8 markers to enhance the predictive value of cancer diagnostics. This innovative approach allows for more accurate and personalized treatment plans, ultimately aiming to improve survival rates and quality of life for cancer patients.
Keywords: immuno-oncology, diagnostics, immune contexture, colorectal cancer, Immunoscore, predictive accuracy, personalized treatment, clinical centers, oncology, healthcare providers.